Psilocybin-Assisted Therapy for Intergenerational Trauma

Recruiting now · Phase 2

Conditions studied: Psychological Stress, Depression, Anxiety

In brief

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Key facts

Study ID

NCT06899165

Run by

Rachel Yehuda

People needed

100

Starts

2025-08-28

Expected to finish

2030-01-02

Last updated by the study team

2025-09-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at least 18 years old at time of signing the informed consent
• Biological child of at least one parent who directly survived/escaped a genocide
• Meets diagnostic criteria for a depressive or anxiety disorder
• Capable of providing informed consent and complying with study procedures
• Currently using or agreeing to use adequate contraceptive methods.
• Fluent in speaking and reading English
• Able to swallow pills
• Agrees to have study visits recorded with audio and video
• Able to provide a contact person who can be reached by investigators in the event of the participant becoming unwell or unreachable
• Agrees to inform the investigators within 48 hours of any medical conditions and procedures
• Agrees to release of outside medical and psychiatric records
• Must not participate in any other interventional clinical trials for the duration of the study.
• Must commit to medication dosing, therapy, and all study procedures.

You may not qualify if…

• Not able to give adequate informed consent.
• Was directly exposed to or survived a genocide.
• Has a history of any medical condition, or any significant clinical finding on screening tests, that could make receiving psilocybin harmful.
• Has acute, severe or unstable medical illness.
• Has a history of stroke or Transient Ischemic Attack (TIA).
• Has a history of psychiatric hospitalization within the last 6 months.
• Current serious suicide risk.
• Unable or unwilling to safely taper off prohibited psychiatric medications.
• Abusing alcohol or other substances.
• Has used psychedelics within 3 months of enrollment.
• Are pregnant or nursing or able to become pregnant and are not practicing an effective means of contraception.

Where it is running

• The Parsons Research Center for Psychedelic Healing — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.